What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.
대표청구항▼
1. A pharmaceutical composition, comprising i. a first glyceride mixture comprising one or more glycerides selected from the group consisting of (a) polyglyceryl-2-diisostearate; (b) a mixture of caprylic, capric, myristic, and stearic triglycerides; (c) bis-diglyceryl polyacyladipate-1; (d) glycery
1. A pharmaceutical composition, comprising i. a first glyceride mixture comprising one or more glycerides selected from the group consisting of (a) polyglyceryl-2-diisostearate; (b) a mixture of caprylic, capric, myristic, and stearic triglycerides; (c) bis-diglyceryl polyacyladipate-1; (d) glyceryl ricinoleate; (e) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids; and (f) triglycerides of saturated C12-C18 fatty acids; andii. meloxicam, or a fatty acid complex thereof, at a concentration of 5 to 60 wt % in the first glyceride mixture; wherein the pharmaceutical composition consists of a homogenous semi-solid suspension, wherein the semi-solid suspension consists of a soft paste with a viscosity of 50-2000 cPs at 30° C., and wherein the semi-solid suspension forms a depot that releases meloxicam for over two weeks when measured in vitro at 37° C. 2. The pharmaceutical composition of claim 1, further comprising a second glyceride mixture consisting of one or more glycerides selected from the group consisting of (a) a mixture of caprylic, capric, myristic, and stearic triglycerides; (b) glyceryl ricinoleate; (c) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids; and (d) triglycerides of saturated C12-C18 fatty acids, wherein the second glyceride mixture has a lower or higher hydrophilic-lipophilic balance (HLB) than the first glyceride mixture, wherein meloxicam is released from the depot for over two weeks when measured in vitro at 37° C. 3. The pharmaceutical composition of claim 2, wherein the concentration of the second glyceride mixture is 1-50 wt % of the pharmaceutical composition. 4. A method for treating a disease or disorder comprising locally administering the pharmaceutical composition of claim 1 by subcutaneous, intramuscular, or intraperitoneal injection. 5. The method of claim 4, wherein the-injection is by a 21 gauge to 27 gauge needle. 6. A method of manufacturing a pharmaceutical composition, comprising i selecting-a first glyceride mixture comprising one or more glycerides selected from the group consisting of (a) polyglyceryl-2-diisostearate; (b) a mixture of caprylic, capric, myristic, and stearic triglycerides; (c) bis-diglyceryl polyacyladipate-1; (d) glyceryl ricinoleate; (e) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids; and (f) triglycerides of saturated C12-C18 fatty acids; andii homogeneously mixing meloxicam in the semi-solid mixture to 5 to 60 wt % of the pharmaceutical composition; wherein the pharmaceutical composition consists of a homogenous semi-solid suspension, wherein the semi-solid suspension consists of a soft paste with a viscosity of 50-2000 cPs at 30° C., and wherein the semi-solid suspension forms a depot that releases meloxicam for over two weeks when measured in vitro at 37° C. 7. The process of claim 6, further comprising iii measuring the release kinetics and duration of meloxicam from the semi-solid mixture of step iii in vitro at 37° C., andiv mixing the product of step iii with a second glyceride mixture comprising one or more glycerides selected from the group consisting of (a) a mixture of caprylic, capric, myristic, and stearic triglycerides; (b) glyceryl ricinoleate; (c) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids; and (d) triglycerides of saturated C12-C18 fatty acids, wherein the second glyceride mixture has a lower or higher HLB (hydrophobicity) than the first glyceride mixture, and wherein meloxicam is released from the depot for over two weeks.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (8)
Bannister, Robin M.; Brew, John; Caparros-Wanderely, Wilson; Dilly, Suzanne J.; Pleguezeulos Mateo, Olga; Stoloff, Gregory A., Compositions for treating chronic inflammation and inflammatory diseases.
Heller Jorge (Woodside CA) Ng Steve Y. W. (San Francisco CA) Penhale Donald W. H. (Menlo Park CA), Polymers containing carboxy-ortho ester and ortho ester linkages.
Heller Jorge (Palo Alto CA) Helwing Robert F. (Sunnyvale CA) Penhale Donald W. (Cupertino CA), Polymers of di- (and higher functionality) ketene acetals and polyols.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.